Related Experiment Video
Updated: Aug 2, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Landmark trials in lipid reduction
1Atlanta VA Medical Center, Decatur, GA 30033, USA.
Insights
Lipid-lowering therapies significantly reduce cardiovascular events in coronary heart disease patients. Recent trials confirm reduced coronary death rates with cholesterol reduction, aiding primary prevention in high LDL cholesterol individuals.
Area of Science:
- Cardiology
- Preventive Medicine
- Lipid Metabolism
Background:
- Epidemiological evidence supports lipid reduction for coronary heart disease (CHD) benefits.
- Landmark trials consistently demonstrate efficacy of lipid-lowering therapies in reducing cardiovascular events.
Purpose of the Study:
- To synthesize current evidence on the impact of lipid reduction on cardiovascular outcomes.
- To address remaining questions regarding lipid intervention's effect on mortality and primary prevention.
Main Methods:
- Review of major clinical trials and epidemiological studies on lipid-lowering therapies.
- Analysis of data concerning cardiovascular event reduction and mortality rates.
Main Results:
- Lipid-lowering therapies significantly reduce major cardiovascular events in patients with high and moderate low-density lipoprotein (LDL) cholesterol.
- Recent trials confirm a decrease in coronary death rates following plasma cholesterol reduction.
- Primary prevention shows benefits for high LDL cholesterol, with more data needed for moderate levels.
Conclusions:
- Lipid reduction is a proven strategy for secondary prevention in coronary patients.
- Further research is required to fully elucidate benefits for primary prevention and cholesterol levels below normal.
- Ongoing research will optimize patient outcomes through lipid interventions.
Abstract:
Since the first epidemiological evidence on the benefit of lipid reduction in coronary heart disease (CHD) was gathered, a number of questions have emerged in this field of research. Consistent findings across a number of landmark trials have shown that lipid-lowering therapies significantly reduced major subsequent cardiovascular events in coronary patients with high and moderate low density lipoprotein (LDL) blood cholesterol levels. Although there has been some confusion on the effect of lipid intervention on mortality, recently definite answers have come from several major trials that establish a clear decrease in coronary death for patients after reduction of plasma cholesterol levels. Primary prevention in individuals with high LDL cholesterol levels was shown to be beneficial in terms of cardiovascular event reduction; more data are needed to address this issue for subjects with moderate LDL cholesterol levels. Reduction of LDL cholesterol below normal levels appeared to be beneficial for coronary patients, but again, further research is needed to elucidate this point. To date, major trials have answered some of the many questions pertaining to lipid-lowering therapies; further research will continue to provide information and allow patients to benefit maximally from lipid interventions.
Related Concept Videos
01:06Lipid Digestion
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:18Lipids: Dietary Sources and Requirements
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...